About Us

Contact Us

Race
Home About Us Product News Order Career Contact

                                                                                                            

           APIs&Intermediates Chemicals of Shanghai APIs Chemical Co., Ltd  

          

Product Indentification
 

Name:   ABT888
Synonyms:   Veliparib
CAS Registry Number:   912444-00-9 or 912445-05-7
Molecular Formula:   C13H16N4O
Molecular Weight:    244.29
Molecular Structure:  

 

 

                    In stock!Bulk!          

 

                   Appearance:  white solid

 

 

                   Purity:99%min

 

              

                   ee:99% min

 

 

                   For Research Used Only

 

 

                   Inquiry (H1NMR,HPLC,LC-MS)

 

 

                   The process of ABT888(CAS#912444-00-9)

 

 

Related PARP Pathway Inhibitors:

 

 

          BSI-201|160003-66-7

 

         AG-14699|459868-92-9   

 

         ABT888|912444-00-9  

 

         Olaparib|AZD-2281|CAS:763113-22-0  

  

          INO-1001|3544-24-9

 

          66611-37-8|BGP-15

          A-966492|934162-61-5

 


 

Related pages:


     Search ABT888 in google
     Search CAS 912444-00-9  or 912445-05-7  in google
     Search C13H16N4O in google

 

Related info:

 

        ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2and 2.9 nmol/L, respectively. The comp-ound has good oral bioavailability and crosses the blood-brain barrier. ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model. PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. In the 9L orthotopic rat gliomamodel, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression. In the MX-1 breast xenograft model(BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited. Finally, ABT-888 potentiated radiation (2 Gy/d 10) in an HCT-116 colon carcinoma model. In each model, ABT-888 did not display single-agentactivity.

        

       

 

 

Home About Us Product News Order Career Contact
 Copyright @ 2010-2011 APIs All rights reserved
 

 

 

No_Right_Click

 

No_Right_Click